52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
FDA Delays Moderna Covid-19 Vaccine For Adolescents To Review Rare Myocarditis Side Effect - WSJ
Moderna Inc Announces Covax Exercises Option To Purchase 176.5 Mln Additional Doses Of Moderna’S COVID-19 Vaccine For Low Income Countries
U.S. CDC ACIP To Meet On Oct. 20-21 To Discuss Covid-19 Vaccine Boosters For Modern, J&J
Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger RNA (mRNA). The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. The Company develops technologies that enable the development of mRNA medicines for diverse applications. The Company has created modalities, including Prophylactic vaccines, Systemic secreted and cell surface therapeutics, Cancer vaccines, Intratumoral immuno-oncology, Localized regenerative therapeutics, and Systemic intracellular therapeutics. Its diverse development pipeline which consists of 27 development candidates across its 24 programs.
Biotechnology & Drugs
200 Technology Sq
Noubar B. Afeyan
Non-Executive Independent Chairman of the Board, Co-Founder
Chief Executive Officer, Director
Chief Financial Officer
Chief Human Resources Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
The U.S. health regulator is delaying its decision on authorizing Moderna Inc's COVID-19 vaccine for adolescents to check if the shot could increase the risk of a rare inflammatory heart condition, the Wall Street Journal reported on Friday.
The U.S. health regulator is delaying a decision on authorizing Moderna Inc's COVID-19 vaccine for adolescents to assess whether the shot may lead to heightened risk of heart inflammation, the Wall Street Journal reported on Friday, citing people familiar with the matter...
Pfizer Inc and BioNTech SE have asked U.S. regulators to authorize their COVID-19 vaccine for emergency use in children aged 5-11, with an expert panel to the Food and Drug Administration scheduled to meet later this month to review data.
A panel of expert advisers to the U.S. Food and Drug Administration unanimously voted on Thursday to recommend booster shots of Moderna Inc's COVID-19 vaccine for Americans aged 65 and older and those at high risk of severe illness or occupational exposure to the virus.
The United States has donated 3.6 million doses of the Pfizer Inc/BioNTech COVID-19 vaccine to Nigeria, two months after it shipped Moderna Inc vaccines to Africa's most-populous nation, a local television station reported on Thursday.
A panel of expert advisers to the U.S. Food and Drug Administration voted on Thursday to recommend booster shots of Moderna Inc's COVID-19 vaccine for Americans aged 65 and older and those at high risk of severe illness.
People who got Johnson & Johnson Inc’s COVID-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer Inc/BioNTech SE or Moderna Inc, a study run by the National Institutes of Health showed on Wednesday.
Scientists at the U.S. Food and Drug Administration said on Tuesday that Moderna Inc had not met all of the agency's criteria to support use of booster doses of its COVID-19 vaccine, possibly because the efficacy of the shot's first two doses has remained strong.
Rwanda, Senegal and South Africa could be potential locations for Moderna's planned vaccine factory in Africa, the U.S. drugmaker's co-founder and chairman said as it steps up its search for a site on the continent.
Moderna Inc on Tuesday said the U.S. Food and Drug Administration should authorize booster doses of its COVID-19 vaccine in fully vaccinated older adults and other high-risk individuals.
Independent advisers to the U.S. Centers for Disease Control and Prevention will meet later this month to make recommendations on booster doses of Moderna Inc and Johnson & Johnson's COVID-19 vaccines, the agency said on Friday.
The U.S. Centers for Disease Control and Prevention's panel of vaccine advisers plans to meet on Oct. 20-21 to discuss COVID-19 vaccine boosters using Moderna and Johnson & Johnson shots, an agency spokesperson said on Friday.
Moderna Inc said on Friday it aims to deliver one billion doses of its COVID-19 vaccine to low-income countries in 2022, in addition to the doses it has already committed to the global vaccine-sharing platform COVAX.
Moderna Inc said on Friday it was looking to deliver another 1 billion doses of its COVID-19 vaccine to low-income countries in 2022. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Saumyadeb Chakrabarty)
The Danish Health Agency said on Friday that it was continuing to offer Moderna's COVID-19 vaccine to under-18s, and that a statement on Wednesday suggesting a suspension had in fact been a miscommunication.
Finland on Thursday paused the use of Moderna's COVID-19 vaccine for younger males due to reports of a rare cardiovascular side effect, joining Sweden and Denmark in limiting its use.
Moderna plans to invest up to $500 million to build a factory in Africa to make up to 500 million doses of mRNA vaccines each year, including its COVID-19 shot, as pressure grows on the pharmaceutical industry to manufacture drugs on the continent.
Finland will pause the use of Moderna's COVID-19 vaccine for men born in 1991 and later due to reports of a rare cardiovascular side effect, the institute for health and welfare said on Thursday.
Moderna plans to invest about $500 million to build a factory in Africa to make up to 500 million doses of mRNA vaccines each year, it said on Thursday.
Sweden and Denmark said on Wednesday they are pausing the use of Moderna's COVID-19 vaccine for younger age groups after reports of possible rare cardiovascular side effects.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.